Full size image available through contact |
CHAPEL HILL -- The American Society for Pharmacology and Experimental Therapeutics has named Dr. David P. Siderovski, assistant professor of pharmacology in The University of North Carolina at Chapel Hill School of Medicine, the recipient of the 2004 John J. Abel Award.
Siderovski, a member of the UNC Lineberger Comprehensive Cancer Center and the UNC Neuroscience Center, "receives the award as an outstanding young investigator for his contributions that helped shape the field of pharmacology," society officials said.
In 1996, while head of the Quantitative Biology Laboratory at the Amgen Institute in Toronto, Siderovski discovered a new family of proteins, RGS proteins, that accelerates the shutoff of cell signaling pathways.
He continues his basic research program at UNC using biochemistry, structural biology and genetics to understand how RGS proteins control the timing of physiological events. His studies are aimed at drug target discovery and drug development.
The award, sponsored by Eli Lilly and Co., is considered the most prestigious award for young scientists in pharmacology and experimental therapeutics.
This is Siderovski's third national career award since joining the UNC faculty in 1999. He was named a Year 2000 Neuroscience Scholar by the EJLB Foundation of Montreal and in 2001 received a New Investigator Award in Basic Pharmacological Sciences by the Burroughs Wellcome Fund.
Siderovski receives the newest award, which carries a $2,500 stipend, April 17 at the society's annual meeting in Washington, D.C. note: contact Siderovski at 843-9363 or david_siderovski@med.unc.edu School of Medicine contact, Les Lang, 919-843-9687 or llang@med.unc.edu